Figure 1.
(A) Progression free survival (PFS) and (B) overall survival (OS) for patients treated with daratumumab and durvalumab. PFS and OS were estimated using the Kaplan-Meier method.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.